Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) shares rose 1.7% on Monday . The company traded as high as $39.44 and last traded at $38.63. Approximately 346,580 shares traded hands during trading, an increase of 592% from the average daily volume of 50,104 shares. The stock had previously closed at $37.99.
Neoleukin Therapeutics Stock Performance
The company has a market capitalization of $383.81 million, a PE ratio of -13.13 and a beta of 1.11. The stock’s 50-day simple moving average is $35.17 and its 200 day simple moving average is $27.75.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc is a clinical‐stage biotechnology company focused on the design and development of de novo protein therapeutics for the treatment of cancer and immune‐mediated diseases. Leveraging computational protein engineering, the company creates novel cytokine mimetics intended to provide targeted immune activation while minimizing the toxicities associated with natural cytokines. This platform is anchored by proprietary algorithms and structure‐based design tools that enable the rapid generation of therapeutic candidates with optimized stability, affinity and specificity.
The company’s lead candidate, NL-201, is a next‐generation cytokine therapy designed to engage interleukin‐2 and interleukin‐15 receptors on immune effector cells, with the goal of enhancing anti‐tumor responses.
See Also
- Five stocks we like better than Neoleukin Therapeutics
- Looking Beyond NVIDIA? These 3 AI ETFs Are Beating the Market
- Palantir’s Kool-Aid Moment: The Math Behind Karp’s Forecast
- OpenAI’s Jalapeño Chip Could Change the AI Hardware Race
- Gold and Bitcoin Are Rebounding—2 ETFs Give Investors a Different Kind of Exposure
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
